Board Meeting Outcome
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vista Pharmaceuticals reported audited results for FY25 with revenue from operations of ₹1,007.46 lakhs, a slight decline of about 2% from ₹1,028.78 lakhs in FY24. The company posted a net loss of ₹464.87 lakhs for FY25, widening from a loss of ₹451.20 lakhs in the previous year, with EPS of ₹(0.79). Q4 FY25 revenue grew sharply to ₹323 lakhs from ₹255.5 lakhs in Q4 FY24, but the company still reported a quarterly loss of ₹149.57 lakhs. Operating cash flow was deeply negative at ₹(698.46) lakhs, while the company raised fresh funds through share capital and borrowings to shore up liquidity. The statutory auditor issued an unmodified/unqualified opinion, and the board also appointed new internal and secretarial auditors. The company noted it has received WHO certification.
Persistent losses, deeply negative operating cash flow, and reliance on fresh equity and borrowings to stay afloat are negative signals for shareholders. While the auditor gave a clean opinion and revenue grew strongly in Q4, the full-year picture remains weak with widening losses.